Topical cream for EGFR inhibitor skin rash in cancer patients
Part of Infections, Skin clinical trials.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and are taking an approved EGFR inhibitor for cancer
- You currently have an EGFR-inhibitor skin rash (mild to moderate), affecting 30% or less of your skin
- Your rash is not severe (not the highest grade), and your overall sickness is mild (CTCAE/ARIGA severity up to 3)
- You are well enough to do usual activities (ECOG performance status 0–2) and are expected to live at least 3 months
- You can use reliable birth control and you can attend required visits (phone/video and in-person)
- You can sign consent after understanding the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a moisturizing cream (with pre- and postbiotics and niacinamide) to see if it reduces dryness and itching in cancer patients who are on a type of targeted therapy called anti-EGFR drugs. If you have dry, itchy skin from your treatment, this cream might help soothe it.
This study tests a new cream, ATR04-484, to see if it can help with skin rashes caused by certain cancer medications (EGFR inhibitors, KRAS inhibitors, or MEK inhibitors). If you have a moderate to severe rash on your face or other areas from these drugs, this trial may offer a new way to ease your symptoms.
This trial tests a new gel (TAR-0520) for treating a bothersome, acne-like rash that often occurs on the face, scalp, or upper chest during cancer treatment with cetuximab or panitumumab. The goal is to see if it helps reduce the rash without affecting your cancer treatment.
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
This trial tests whether extra care to prevent skin and infusion side effects helps people with advanced lung cancer who are getting amivantamab (with lazertinib or chemotherapy). It aims to make these treatments easier to tolerate.
This study tests an oral medication called erlotinib (an EGFR inhibitor) to see if it can reduce the skin symptoms of keratinopathies like epidermolytic ichthyosis, epidermolytic palmoplantar keratoderma, and pachyonychia congenita. The goal is to improve skin condition and quality of life.
Hear when a new Acneiform Eruption Due to Chemical trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.